Trial Results

August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
November 16, 2021

Trial Results: ASCO Highlights Practice-Changing Results in Melanoma

The phase 3 DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
January 25, 2021

Joe Sparano: Refining Individual Risk in Breast Cancer

Dr. Sparano discusses the scientific and statistical collaboration behind a new tool, RSClin™, which integrates clinical–pathological and genomic risk information to guide adjuvant chemotherapy in node-negative breast cancer
October 19, 2020

Trial Results: Genomic study of 6000 NCI-MATCH cancer patients leads to new clinical trial benchmarks

The Journal of Clinical Oncology published new data from the NCI-MATCH precision medicine cancer trial that has broad relevance in medicine and provides a roadmap for future precision medicine trials